Africa Large Volume Parenterals (LVP) Market Overview:

The Africa large volume parenterals (LVP) market was valued at $662 million in 2017, and is expected to reach $1,133 million by 2024, growing at a CAGR of 7.9% from 2018 to 2024. In terms of volume, the market garnered 291,095 thousand units in 2017, and is expected to reach 582,780 thousand units by 2024, growing with a CAGR of 10.4% from 2018 to 2024.

Get more information on this report : Request Sample Pages

The growth of the Africa large volume parenterals market is driven by rise in prevalence of chronic diseases such as cancer, HIV, and other non-communicable diseases; rapid surge in number of surgeries; and rise in risk of malnutrition. However, preference for enteral route of drug administration of therapeutic & nutritional needs and high risk of infection/allergic reaction during a parenteral administration are expected to impede the market growth. Conversely, upsurge in demand for palliative care services in Africa is expected to offer opportunities for market expansion during the forecast period.

Africa Large Volume Parenterals Market Segmentation

The Africa large volume parenterals market is segmented on the basis of treatment type, route of administration, capacity, and country. On the basis of treatment type, the market is classified into fluid balance injections, therapeutic injections, and nutritious injections. Depending on route of administration, it is fragmented into intravenous, intramuscular, subcutaneous, and other routes. LVP are commercially available in 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml bottles. Country wise, the market is analyzed across South Africa, Zimbabwe, Namibia, and rest of Africa.

Segment review

Fluid balance injection is the most commonly used treatment type, owing its wide applications such as fluid resuscitation, routine maintenance, replacement, and redistribution. Fluid resuscitation refers to the restoration of circulation to vital organs after loss of intravascular fluids due to bleeding, plasma loss, or excessive external fluid & electrolyte loss. Parenteral preparations are required by patients who cannot meet their normal fluid or electrolyte needs by oral/enteral routes. These patients need to undergo IV therapy for routine maintenance of bodily fluids and electrolytes. In addition, LVP may be needed for internal fluid distribution changes in case of edema or abnormal fluid handling by the organ systems. Fluid redistribution is required in patients who are critically ill, septic, with major cardiac, liver or renal comorbidity, or after a major surgery.

Get more information on this report : Request Sample Pages

Based on route of administration, the market is fragmented into intravenous, intramuscular, subcutaneous, and other routes. Intravenous (IV) route is the most commonly used route, and serves as the fastest way to deliver large volume parenterals, as the drug is easily carried throughout the body with the help of circulation.

Furthermore, the market is analyzed for volume of large volume parenterals by capacity, i.e. 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml bottles.

Get more information on this report : Request Sample Pages

Snapshot of South Africa large volume parenterals market

South Africa has one of the most advanced palliative care systems in Africa, as it has an extensive network of hospice organizations that provide care to people suffering from chronic and life-threatening illnesses. For instance, palliative care is required in the end stage of cancer, lung diseases, diabetes, and cardiac diseases. In addition, rise in prevalence of non-communicable diseases is expected to drive the market growth. However, according to the South African Health News Service, most of the palliative care facilities in South Africa focus on cancer and HIV patients as compared to other conditions. Thus, South African healthcare organizations are expected to expand their palliative care facilities for patients suffering from other non-communicable or life-threatening disorders, which would further propel the growth of the market.

Get more information on this report : Request Sample Pages

The key local players within Africa large volume parenterals market include Abacus Parenteral Drugs Limited, Erongo Med, Datlabs Private Limited, Addis Pharmaceuticals Factory PLC, Pharmacure PLC, Mascareignes Pharmaceutical Manufacturing Co. Ltd. (operates as a subsidiary of Parenteral Drug (India) Ltd.), and Adcock Ingram Holdings Ltd.

Key Benefits

• The study provides an in-depth analysis of the market with current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2017 to 2023, which is expected to enable the stakeholders to capitalize on prevailing market opportunities.
• Analysis by route of administration helps to understand the various routes for administration of parenteral drugs within the body.
• Comprehensive analysis of major countries within Africa is provided to determine the prevailing opportunities.
• Key players are profiled, and their strategies are analyzed thoroughly to understand the competitive outlook of the market.

 Key Market Segments

• By Treatment Type
  • Fluid Balance Injections
  • Therapeutic Injections
  • Nutritious Injections
• By Route Of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Other routes
• By Capacity
  • 100 ml
  • 250 ml
  • 500 ml
  • 1000 ml
  • 2000 ml
• By Country
  • South Africa
  • Zimbabwe
  • Namibia
  • Rest of Africa

 
Key Market Players

• Adcock Ingram Holdings Ltd.
• Abacus Parenteral Drugs Limited
• Addis Pharmaceutical Factory PLC.
• Erongo Med
• Datlabs Private Limited
• Pharmacure PLC
• Parenteral Drugs (India) Ltd.

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. Key Findings

3.2.1. Top investment pockets
3.2.2. Top player positioning, 2016

3.3. MARKET DYNAMICS

3.3.1. Drivers

3.3.1.1. Increase in number of surgical procedures
3.3.1.2. Rise in prevalence of chronic diseases
3.3.1.3. Rise in risk of malnutrition

3.3.2. Restraints

3.3.2.1. Risk of allergic reaction and infection
3.3.2.2. Preference for enteral route of administration

3.3.3. Opportunities

3.3.3.1. Upsurge in demand for palliative care

CHAPTER 4: AFRICA LARGE VOLUME PARENTERALS MARKET, BY TREATMENT TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Fluid balance injections

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast

4.3. Therapeutic Injections

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast

4.4. Nutritious injections

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast

CHAPTER 5: AFRICA LARGE VOLUME PARENTERALS MARKET, BY ROUTE OF ADMINISTRATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Intravenous

5.2.1. Market size and forecast

5.3. Intramuscular

5.3.1. Market size and forecast

5.4. Subcutaneous

5.4.1. Market size and forecast

5.5. Other routes

5.5.1. Market size and forecast

CHAPTER 6: AFRICA LARGE VOLUME PARENTERALS MARKET, BY CAPACITY

6.1. Overview

6.1.1. Market size and forecast

6.2. 100 ml

6.2.1. Market size and forecast

6.3. 250 ml

6.3.1. Market size and forecast

6.4. 500 ml

6.4.1. Market size and forecast

6.5. 1000 ml

6.5.1. Market size and forecast

6.6. 2000 ml

6.6.1. Market size and forecast

CHAPTER 7: AFRICA LARGE VOLUME PARENTERALS MARKET, BY COUNTRY

7.1. Overview

7.1.1. Market size and forecast

7.2. South Africa

7.2.1. Market size and forecast

7.3. Zimbabwe

7.3.1. Market size and forecast

7.4. Namibia

7.4.1. Market size and forecast

7.5. Rest of Africa

7.5.1. Market size and forecast

CHAPTER 8: COMPANY PROFILE

8.1. Parenteral Drugs (India) Ltd.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. Adcock Ingram Holdings Ltd.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance

8.3. Pharmacure PLC

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Product portfolio

8.4. Datlabs Private Limited

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio

8.5. Erongo Med

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio

8.6. Addis Pharmaceutical Factory PLC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Key strategic moves and developments

8.7. Abacus Parenteral Drugs Limited

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Product portfolio

LIST OF TABLES

TABLE 01. TOTAL SURGICAL NEED IN SUB-SAHARAN AFRICA, 2010
TABLE 02. MINIMUM UNMET NEED FOR SURGICAL CASES IN SUB-SAHARAN AFRICA, 2010
TABLE 03. AFRICA LARGE VOLUME PARENTERALS MARKET, BY TREATMENT TYPE, 2017-2024 ($MILLION)
TABLE 04. AFRICA LARGE VOLUME PARENTERALS MARKET, BY ROUTE OF ADMINISTRATION, 2017-2024 ($MILLION)
TABLE 05. OTHER ROUTES OF PARENTERAL ADMINISTRATION
TABLE 06. AFRICA LARGE VOLUME PARENTERALS VALUE MARKET, BY CAPACITY, 2017-2024 ($MILLION)
TABLE 07. AFRICA LARGE VOLUME PARENTERALS VOLUME MARKET, BY CAPACITY, 2017-2024 (THOUSAND UNITS)
TABLE 08. AFRICA LARGE VOLUME PARENTERALS MARKET, BY COUNTRY, 2017-2024 ($MILLION)
TABLE 09. PDIL: COMPANY SNAPSHOT
TABLE 10. PDIL: PRODUCT CATEGORY
TABLE 11. PDIL: PRODUCT PORTFOLIO
TABLE 12. ADCOCK INGRAM: COMPANY SNAPSHOT
TABLE 13. ADCOCK INGRAM: OPERATING SEGMENTS
TABLE 14. PHARMACURE: COMPANY SNAPSHOT
TABLE 15. DATLABS: COMPANY SNAPSHOT
TABLE 16. DATLABS: PRODUCT CATEGORY
TABLE 17. DATLABS: PRODUCT PORTFOLIO
TABLE 18. ERONGO MED: COMPANY SNAPSHOT
TABLE 19. ERONGO MED: PRODUCT CATEGORY
TABLE 20. ERONGO MED: PRODUCT PORTFOLIO
TABLE 21. APF: COMPANY SNAPSHOT
TABLE 22. APF: PRODUCT CATEGORY
TABLE 23. APF: PRODUCT PORTFOLIO
TABLE 24. APDL: COMPANY SNAPSHOT
TABLE 25. APDL: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. AFRICA LVP MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS, 2017
FIGURE 03. TOP PLAYER POSITIONING, 2017
FIGURE 04. AFRICA LARGE VOLUME PARENTERALS MARKET FOR FLUID BALANCE INJECTIONS, 2017-2024 ($MILLION)
FIGURE 05. AFRICA LARGE VOLUME PARENTERALS MARKET FOR THERAPEUTIC INJECTIONS, 2017-2024 ($MILLION)
FIGURE 06. AFRICA LARGE VOLUME PARENTERALS MARKET FOR NUTRITIOUS INJECTIONS, 2017-2024 ($MILLION)
FIGURE 07. AFRICA LARGE VOLUME PARENTERALS MARKET, BY ROUTE OF ADMINISTRATION
FIGURE 08. AFRICA LARGE VOLUME PARENTERALS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, 2017-2024 ($MILLION)
FIGURE 09. AFRICA LARGE VOLUME PARENTERALS MARKET FOR INTRAMUSCULAR ROUTE OF ADMINISTRATION, 2017-2024 ($MILLION)
FIGURE 10. AFRICA LARGE VOLUME PARENTERALS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, 2017-2024 ($MILLION)
FIGURE 11. AFRICA LARGE VOLUME PARENTERALS MARKET FOR OTHER ROUTES OF ADMINISTRATION, 2017-2024 ($MILLION)
FIGURE 12. AFRICA LARGE VOLUME PARENTERALS MARKET FOR 100 ML BOTTLES, BY VALUE AND VOLUME, 2017-2024 ($MILLION)
FIGURE 13. AFRICA LARGE VOLUME PARENTERALS MARKET FOR 250 ML BOTTLES, BY VALUE AND VOLUME, 2017-2024 ($MILLION)
FIGURE 14. AFRICA LARGE VOLUME PARENTERALS MARKET FOR 500 ML BOTTLES, BY VALUE AND VOLUME, 2017-2024 ($MILLION)
FIGURE 15. AFRICA LARGE VOLUME PARENTERALS MARKET FOR 1000 ML BOTTLES, BY VALUE AND VOLUME, 2017-2024 ($MILLION)
FIGURE 16. AFRICA LARGE VOLUME PARENTERALS MARKET FOR 2000 ML BOTTLES, BY VALUE AND VOLUME, 2017-2024 ($MILLION)
FIGURE 17. SOUTH AFRICA LARGE VOLUME PARENTERALS MARKET, 2017-2024 ($MILLION)
FIGURE 18. ZIMBABWE LARGE VOLUME PARENTERALS MARKET, 2017-2024 ($MILLION)
FIGURE 19. NAMIBIA LARGE VOLUME PARENTERALS MARKET, 2017-2024 ($MILLION)
FIGURE 20. REST OF AFRICA LARGE VOLUME PARENTERALS MARKET, 2017-2024 ($MILLION)
FIGURE 21. PDIL: NET SALES, 2014-2016 ($MILLION)
FIGURE 22. ADCOCK INGRAM: NET SALES, 2015-2017 ($MILLION)
FIGURE 23. ADCOCK INGRAM: REVENUE SHARE BY SEGMENT, 2017 (%)